Race Oncology Ltd. (AU:RAC)

ASX:RAC

RAC

Race Oncology Ltd.

RESEARCH TOOLSreports

Race Oncology Ltd. (RAC) Price & Analysis

33 Followers

RAC Stock Chart & Stats

AU$2.70

-AU$0.03(-2.27%)

At close: Jan 09 4:00 PM EST

AU$2.70

-AU$0.03(-2.27%)

Day’s Range― - ―

52-Week RangeAU$0.92 - AU$4.90

Previous CloseN/A

Volume68.10K

Average Volume (3M)373.28K

Market Cap

AU$479.29M

Enterprise ValueAU$457.64M

Total Cash (Recent Filing)AU$20.94M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding182,240,540

10 Day Avg. Volume310,625

30 Day Avg. Volume373,283

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)12.69

Price to Sales (P/S)33.63

P/FCF Ratio-44.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt materially reduces refinancing and interest-rate risks for a development-stage biotech. This preserves financial flexibility to fund clinical programs or partnerships, lowering bankruptcy risk and supporting multi-quarter development timelines without immediate leverage pressure.

Improving Loss And Cash-burn TrendsNarrowing losses and reduced cash burn indicate operational improvement and better cash stewardship. Sustained improvement increases runway and the probability management can reach upcoming clinical or commercial inflection points with less frequent capital raises over the next several quarters.

High Gross Margin In FY2025Strong gross margins imply that incremental revenue is likely to flow to the bottom line once fixed R&D and SG&A are controlled. For a biotech, durable high gross margins can enable operating leverage as revenues scale or as licensing/commercial deals materialize.

Bears Say

Persistent Negative Cash FlowOngoing negative operating and free cash flow means the company is not self-funding its development program and will likely need external capital. That creates dilution risk, constrains discretionary R&D or commercialization spend, and raises long-term sustainability concerns.

Volatile And Declining RevenueA sharp revenue decline and volatility point to an uncertain commercialization path or lumpy milestone-driven income. Structural revenue instability impairs planning, weakens predictability of future margins, and increases execution risk for multi-quarter development strategies.

Eroding Equity And Negative ROEDeclining equity and negative ROE show shareholder capital is being consumed by losses, shrinking the balance-sheet buffer. Over time this limits internal funding capacity and increases likelihood and potential size of dilutive capital raises to support operations or trials.

Race Oncology Ltd. News

Race Oncology Director Boosts Shareholding via $250,000 Option Exercise

Race Oncology Ltd. ( ($AU:RAC) ) just unveiled an announcement. Race Oncology director Daniel Tillett has increased his...

2d ago

RAC

Racura Oncology Seeks ASX Quotation for 270,471 New Shares

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has applied to the...

2d ago

RAC

Racura Oncology Doses First Patient in Phase 1 Lung Cancer Trial of RC220 with Osimertinib

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology has recruited the first patient into...

4d ago

RAC

Racura Oncology posts inaugural R&D symposium video to bolster visibility of late-stage cancer pipeline

Race Oncology Ltd. ( ($AU:RAC) ) has shared an update. Racura Oncology has released a full video recording...

5d ago

RAC

Racura Oncology Seeks ASX Quotation for 163,122 New Shares

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology Ltd has applied to...

9d ago

RAC

Racura taps Purdue expertise to decode MYC-silencing mechanism of (E,E)-bisantrene

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology has entered a research collaboration with...

9d ago

RAC

Racura showcases oncology pipeline at inaugural R&D investor symposium

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology Limited, an ASX-listed Phase 3-stage clinical...

11d ago

RAC

Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology Ltd has applied to the ASX...

16d ago

RAC

Racura Completes First RC220 Dose Cohort in Global Solid Tumour Trial

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has safely dosed the...

16d ago

RAC

Racura to unveil MYC-silencing bisantrene data at AACR 2026

The latest update is out from Race Oncology Ltd. ( ($AU:RAC) ). Racura Oncology will present new preclinical...

17d ago

RAC

RAC FAQ

What was Race Oncology Ltd.’s price range in the past 12 months?

Race Oncology Ltd. lowest share price was AU$0.92 and its highest was AU$4.90 in the past 12 months.

What is Race Oncology Ltd.’s market cap?

Race Oncology Ltd.’s market cap is AU$479.29M.

When is Race Oncology Ltd.’s upcoming earnings report date?

Race Oncology Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 139 days.

How were Race Oncology Ltd.’s earnings last quarter?

Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.

Is Race Oncology Ltd. overvalued?

According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Race Oncology Ltd. pay dividends?

Race Oncology Ltd. does not currently pay dividends.

What is Race Oncology Ltd.’s EPS estimate?

Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Race Oncology Ltd. have?

Race Oncology Ltd. has 182,240,540 shares outstanding.

What happened to Race Oncology Ltd.’s price movement after its last earnings report?

Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.

Which hedge fund is a major shareholder of Race Oncology Ltd.?

Currently, no hedge funds are holding shares in AU:RAC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Race Oncology Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.44%

Trailing 12-Months

Asset Growth

14.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Race Oncology Ltd.

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.